



Impc 03-22-04

CASE 4-30583A

DAC
\$

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EV3558879645	March 26, 2004
Express Mail Label Number	Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1632

AMLOT ET AL.

Examiner: R. Harrison

APPLICATION NO: 09/770,002

FILED: JANUARY 25, 2001

FOR: USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF
RHEUMATOID ARTHRITIS OR SKIN DISEASES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

PETITION TO REVIVE UNDER 37 CFR 1.137(b).

Sir:

Applicants respectfully request that the above-identified application be revived under the provisions of 37 CFR 1.137(b).

This application became abandoned by failure to file a Notice of Appeal to the Final Rejection of April 28, 2003, within the six month statutory period which expired on October 28, 2003.

Enclosed with this Petition is a Notice of Appeal in response to the Final Rejection as required by 37 CFR 1.137(b)(1).

In accordance with 37 CFR 1.137(b)(2), the Commissioner is hereby authorized to charge the fee of \$1,330 required by 37 CFR 1.17(m) to Deposit Account No. 19-0134 in the name of Novartis Corporation. A duplicate copy of this Petition is also enclosed.


In accordance with 37 CFR 1.137(b)(3), it is respectfully submitted that the entire delay in filing the required Notice of Appeal from the due date of October 28, 2003 until the filing of the instant, grantable petition was unintentional.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080

Date: March 26, 2004

Encls.: extra copy of Petition
Notice of Appeal (2)


Susan Hess
Attorney for Applicants
Reg. No. 37,350
Phone No. (862) 778-7859

03/30/2004 AWONDAF1 00000090 190134 09770002

01 FC:1453 1330.00 DA